A healthy, active lifestyle is the goal of many modern consumers. Essential to achieving this are strong bones and joints. As the global population gets older, joint- and bone-related health concerns are becoming increasingly common. Physically active people, such as athletes, can also encounter joint discomfort and injury to connective tissue as a result of high-intensity exercise. In view of this, proactive consumers are looking for ways to maintain healthy joints and bones and are searching for products with added benefits to help maintain their active lifestyles. 


Cartilage is made up of cellular building blocks (chondrocytes), which produce an extracellular matrix, consisting of collagen and proteoglycans (mainly aggrecan). Collagen fibers make up 70-95% of cartilage and are responsible for its structure and strength, while proteoglycans serve as lubricant to the joint. Healthy cartilage is maintained by a finely-balanced process that breaks down collagen and aggrecan and replaces them with a newly-formed matrix. If this balance is interrupted, enzymes can attack collagen and aggrecan leading to a loss of cartilage and joint function.

To maintain healthy joints, it is essential to ensure this balance is protected and the necessary building blocks for collagen are available to support cartilage regeneration. Collagen peptides like Peptan are designed to support this process.

Demonstrated joint health benefits A highly active process of cartilage formation can help to prevent excess matrix degradation and thus help maintain healthy joints. Collagen peptides such as Peptan have been proven to stimulate chrondrocytes to produce more collagen and aggrecan.

A large body of scientific evidence support the efficacy of collagen peptides (type 1) to support connective tissue and promote healthy joints. This evidence include in-vitro, in-vivo, and multiple placebo controlled clinical study.

Peptan has been extensively tested for its regenerative effect on cartilage tissue and demonstrated effect on reducing joint discomfort and stiffness in a double blind placebo controlled study.

Reduced joint pain and improved mobility In a 2013 double-blind, placebo-controlled clinical trial,4 94 female participants aged 40-70 suffering from knee joint pain or discomfort due to osteoarthritis were randomly assigned either 8g of Peptan or a placebo per day for 6 months. Participants were assessed at the beginning of the trial, three months into the trial and at the end of the trial. These assessments were based on two established methods, a standardized questionnaire, the WOMAC score, to measure joint pain and joint function in daily life and the Lysholm score, to evaluate knee joint function when limping, walking, jumping and stair climbing. Participants who were given Peptan reported lowering WOMAC scores over time and recorded significantly lower pain scores at the end of the study. In comparison, no significant change was shown in the placebo group.